



# Patient-Provider Discussion Guide

## How to use this guide

This guide is to help you feel confident and supported as you talk with your healthcare provider.

### Before Your Visit

To help you feel prepared, review the topics below you may want to discuss. Print the “For Providers” handout.

### During Your Visit

Share the “For Providers” handout with your healthcare provider.

### If You're Interested

Ask your healthcare provider if they would order the test for you.

## Helpful topics for discussing The Octave® Multiple Sclerosis Disease Activity (MSDA) Test

### Starting the conversation

I've heard about The Octave MSDA Test. I'd like a better picture of my MS disease activity, including what might be happening under the surface that an MRI may not show. Is this something you offer?

### If your healthcare provider offers the test

Can we talk about whether this test would help guide my MS care?

---

How often do you recommend repeating the test for someone like me?

---

How will you use my results alongside MRI and office visits to adjust my care?

---

I'd like to add The Octave MSDA Test as part of my ongoing monitoring. Would you order this test for me?

### If your healthcare provider is unfamiliar

Share the “For Providers” handout (following pages) and/or share Octave's website, [Octavebio.com](https://www.octavebio.com)

---

#### Key Facts to Highlight

- The Octave MSDA Test is the first and only simple blood test that measures 18 biomarkers linked to MS disease activity.
  - It's already being used by over 400 healthcare providers and supporting over 18,000 patients living with MS. Usage of MSDA Test through January 2026.
- 

I'd like to discuss whether we can include the test in my care plan.

### If your healthcare provider is hesitant

#### Ask

Can you help me understand your concerns about adding the test to my care?

---

What would be the next steps to add the test to my care in the future?

#### Emphasize Your Perspective

Additional information about my MS could give me confidence in how I'm doing and whether my treatment is working.



# The Octave<sup>®</sup> Multiple Sclerosis Disease Activity (MSDA) Test


## The Octave MSDA Test

The first and only analytically<sup>1</sup> and clinically validated,<sup>2</sup> 18 protein biomarker test that provides a disease activity score on the probability of your patient having MRI and clinical activity—empowering more proactive and personalized care.

## The Octave MSDA Score and Report

After your patient completes a simple blood test, you'll receive an AI-enabled, personalized report of their results. The report indicates a disease activity score, comprised of 18 biomarkers with 4 biological pathways.

The Octave MSDA Score provides a numeric value (1–10), categorized as **low**, **moderate**, or **high**, with intuitive color-coding to quickly assess your patient's risk and likelihood of a gadolinium enhancing lesion.



## Score Categories



~20% of patient samples with a Gd+ Lesion<sup>2,4</sup>

Generally, this indicates the patient is at low risk for biological disease activity as evidenced by high probability of minimal or no radiological worsening.

Based on clinical and radiological status of the patient, may repeat testing every 6 months.



~40% of patient samples with a Gd+ Lesion<sup>2,4</sup>

An MSDA Score in this category indicates the probability of radiological activity is greater than in the Low MSDA category, but less than that observed with High MSDA scores.

Continue monitoring with the Octave MSDA test. Based on the clinical and radiological status of the patient, may repeat testing every 3–6 months.



~80% of patient samples with a Gd+ Lesion<sup>2,4</sup>

An MSDA Score in this category indicates the probability of significant radiological disease activity is high.

Based on our retrospective clinical utility study for patients with a high score, 70% of the decision time points, clinicians initiated a Disease-Modifying Therapy (DMT), and 30% of the decision time points led to a switch in DMT.<sup>3</sup>

# 25,000+

Scores delivered

# 400+

Prescribers

# 18,000+

Patients already empowered

Usage of MSDA Test through January 2026

## MS specialists agree The Octave MSDA Test has strong clinical utility in management of MS

### 1 in 5

Time points, clinicians **changed their clinical decision** based on the results of an MSDA Test.<sup>3</sup>

### 69.2%

Of the time, treating clinicians agreed or strongly agreed that longitudinal MSDA results **influenced their decision making**.  $p < 0.001$ ; 95% CI: [60.2, 78.3]<sup>3</sup>

### 59.8%

Of the time, treating clinicians agreed or strongly agreed that **a single MSDA result had an impact on their decision making**.  $p = 0.217$ ; 95% CI: [43.7, 76]<sup>3</sup>

### Clinical use cases

- ✓ DMT initiation and adjustments<sup>3</sup>
- ✓ Longitudinal monitoring
- ✓ Relapse assessment<sup>2</sup>
- ✓ Treatment optimization
- ✓ De-escalation and discontinuation decisions
- ✓ Complement MRI and symptom reporting with objective biomarker data to guide treatment decisions<sup>3</sup>

### Peer-Reviewed publications

**Clinical Validation** | Chitnis T, et al. Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. *Clin Immunol.* 2023;253:10968.

The Octave MSDA Test reliably tracks MS disease activity relative to radiological and clinical endpoints used in standard of care.

**Clinical Utility** | Sanchez A, et al. Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessment in multiple sclerosis. *Mult Scler J Exp Transl Clin.* 2025;11@: 20552173251331030.

Real-world data from 14 clinics, demonstrating clinically impactful decisions and objective insight for MS care.

MOST PATIENTS PAY

# \$100

Or less out-of-pocket

### The Octave Cares Program

Octave accepts all commercial insurance. We believe that financial concerns should never be a barrier to accessing The Octave MSDA Test and have programs design to ensure all patients can afford it.

- ✓ Octave's Financial Assistance Program
- ✓ Dedicated Support Team

1. Qureshi, Ferhan et al. "Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis." *Proteomics. Clinical applications* vol. 17,3 (2023): e2200018. doi:10.1002/prca.202200018 2. Chitnis T, et al. Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. *Clin Immunol.* 2023;253:109688. 3. Sanchez A, et al. Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessment in multiple sclerosis. *Mult Scler J Exp Transl Clin.* 2025;11@:20552173251331030. 4. Kuhle J, et al. Multivariate proteomic MS disease activity test score performance evaluated in an independent focal inflammation cohort. Poster P045 presented at: ACTRIMS Forum; February 24-26, 2022; West Palm Beach, FL.

Contact your Octave representative at [inquiries@Octavebio.com](mailto:inquiries@Octavebio.com) or [Octavebio.com/get-in-touch](https://Octavebio.com/get-in-touch)

# OCTAVE

Learn more at [Octavebio.com](https://Octavebio.com)

© 2026 Octave Bioscience, Inc. 1440 O'Brien Drive, Suite B, Menlo Park, CA 94025 | MK-36 Patient-Provider Discussion Guide